You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

Investigational Drug Information for Savolitinib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Savolitinib?

Savolitinib is an investigational drug.

There have been 34 clinical trials for Savolitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 8th 2021.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and Parexel.

There are fourteen US patents protecting this investigational drug and two hundred and ninety-four international patents.

Recent Clinical Trials for Savolitinib
TitleSponsorPhase
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentSamsung Medical CenterPhase 2
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsParexelPhase 1
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsAstraZenecaPhase 1

See all Savolitinib clinical trials

Clinical Trial Summary for Savolitinib

Top disease conditions for Savolitinib
Top clinical trial sponsors for Savolitinib

See all Savolitinib clinical trials

US Patents for Savolitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Savolitinib ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Savolitinib ⤷  Sign Up Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN) ⤷  Sign Up
Savolitinib ⤷  Sign Up Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Savolitinib ⤷  Sign Up Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, CN) ⤷  Sign Up
Savolitinib ⤷  Sign Up PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Savolitinib ⤷  Sign Up PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Savolitinib ⤷  Sign Up Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile Loxo Oncology Inc. (Stamford, CT) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Savolitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Savolitinib Australia AU2017261372 2036-05-05 ⤷  Sign Up
Savolitinib Canada CA3023278 2036-05-05 ⤷  Sign Up
Savolitinib China CN107847398 2036-05-05 ⤷  Sign Up
Savolitinib European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Savolitinib European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
Savolitinib Hong Kong HK1249728 2036-05-05 ⤷  Sign Up
Savolitinib Japan JP2019520866 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.